Synnöve Lindemalm, MD, PhD, Astrid Lindgren Children's Hospital

Slides:



Advertisements
Similar presentations
6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Advertisements

Safe Supply of Paediatric Unlicensed Medicines
RATIONAL USE OF INJECTION: An Integrated Tool For Monitoring Injection Prescription in the Kingdom of CAMBODIA Dr Sok Srun Department of Hospitals, MoH.
Great Ormond Street Hospital for Children NHS Trust The School of Pharmacy UCL INSTITUTE OF CHILD HEALTH Centre for Paediatric Pharmacy Research Drug Development.
Abstract The Knowledge, Perceptions, and Practice of Pharmacovigilance among Community Pharmacists in Lagos State, Southwest Nigeria Oreagba, Ibrahim Adekunle.
Drivers of antibiotic resistance in Uganda and Zambia Presentation to the Global Health Council, Washington, DC, June 14, 2011 Alliance for the Prudent.
Clinical Pharmacy Basma Y. Kentab MSc..
1 The European Paediatric Initiative Agnès Saint Raymond, MD Scientific Advice and Orphan Drugs The European Medicines Evaluation Agency.
23 augusti 2015Veronica Vicente1 Track 8: Clinical Geriatrics Randomized Controlled Trial of a Prehospital Decision System by Emergency Medical Services.
Unlicensed Medicines in Paediatrics Is there a problem ? Scottish Neonatal and Paediatric Pharmacist Group National Paediatric Pre- Registration Pharmacist.
Implementation of local guideline by interactive workshop improves anticoagulation therapy and patient safety Puhakka J, Helsinki Health Centre, GP Suvanto.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
Information poster for the administration of commonly used medication in dysphagia Emma Lowe, Hilary Oldham, Joan Karasu, Sharon Platt Clinical service.
REGULATION OF CLINICAL TRIALS IN PAEDIATRIC POPULATION DIFFERENCES BETWEEN TRIALS IN ADULTS AND CHILDREN presented by GYURASICS, ÁGNES MD PhD National.
Journal Club/September 24, Swing et al. Television and video game exposure and the development of attention problems. Pediatrics 2010;126:
Results Recruitment 507 out of 4417 patients were eligible to take part in the study 131 of them (25.5%) participated in the study Demographics Male-female.
Safe and Effective Medicine for Children Daring to be Rare, BIOTECanada Panel 2015 CADTH Symposium Saskatoon, April
Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
Depression Screening of Children and Adolescents With Diabetes Lizzy Shaw
Background Objectives Results Methods Within State Geographic Variation in Antipsychotic Medication Treatment for Medicaid-insured Children and Adolescents.
FLAVORx Inc, 9475 Gerwig Lane, Columbia, MD | | 1 PEDIATRIC ADHERENCE.
The competent patient in a paediatric Stem cell Transplant Unit (SCT) and the ethical value of ensuring therapeutic compliance in adolescents. Presenter:
Optimization of psychotropic drug prescription in nursing home patients with dementia: the PROPER study (PRescription Optimization of Psychotropic drugs.
Swallowing medicines: a study of paediatric patients Fatimah Abbas, Aston University.
European Patients’ Academy on Therapeutic Innovation Ethical and practical challenges of organising clinical trials in small populations.
European Patients’ Academy on Therapeutic Innovation Special Populations.
Using Australian Clinical Sites – Challenges for International Sponsors Prof A J (Tony) Webber Clinical Network Services Pty Ltd Brisbane, Australia.
Quality of Drugs in Private Pharmacies in Laos: A Repeated Study in 1997 and 1999 Stålsby Lundborg C, Syhakhang L, Lindgren B, Tomson G International Health.
EVALUATING THE EFFECTIVENESS OF THE AGS UPDATED 2012 BEERS CRITERIA AS AN EDUCATIONAL TOOL IN A FAMILY MEDICINE RESIDENCY TRAINING PROGRAM Eseoghene Abokede.
The transdermal route of delivery has increased in popularity over the past decade with a wide range of medicines now being available [1]. However with.
Children’s Outcomes Research Program The Children’s Hospital Aurora, CO Children’s Outcomes Research Program The Children’s Hospital Aurora, CO Colorado.
Northern Dimension Antibiotic Resistance Study NoDARS Prof Jaana Vuopio, M.D., Ph.D., PAC 11 side-event, 19 November 2015, Berlin, Germany.
+ Interdisciplinary Care in Pediatric Chronic Pain Emily Law, PhD Assistant Professor Department of Anesthesiology & Pain Medicine University of Washington.
Antibiotic use and bacterial complications following upper respiratory tract infections: a population based study.
Off-label Use.
Disclosure of HIV status to children living with HIV in Malawi: needs assessment and formative evaluation of an intervention to help with the disclosure.
Paediatric Medicine: The Paediatric Investigation Plan
BCT Bortezomib Consolidation Trial
Carbamazepine overdosage despite low residual plasma concentration?
Implementing PROMIS in quality Registries
An update on European Paediatric Formulation Initiative (EuPFi)
PAEDIATRIC REGULATION
Fadiea Al-Aieshy   PhD-student, MSc Pharm
Placebo response is not decreased by enrichment trial designs in randomized controlled trials of triptan medications in the paediatric age group Lawrence.
Long term effectiveness of perampanel: the Leeds experience Jo Geldard, Melissa Maguire, Elizabeth Wright, Peter Goulding Leeds General Infirmary, Leeds.
Clinical Trials — A Closer Look
PCI related in-hospital mortality based on race and gender in the USA
ACT at inpatient clinics in Västerås and Stockholm, Sweden
Pediatric pharmacology: why do we need it ?
POLYPHARMACY IN GERIATRIC PATIENTS Dr SHREYAS MISTRY MD, Dr MAYUR RALI MD HOFSTRA-North Shore LIJ School of Medicine Department of Family Medicine Southside.
Facial Affect Recognition in Autism, ADHD and Typical Development
Resource use by pharmacists providing paediatric services
Concepts of Paediatric Investigation Plans (PIP)
Nat. Rev. Nephrol. doi: /nrneph
© FIOH | Mikko Härmä | Working hours, health, well-being and participation in working life (WOW) Creating new working time models and solutions.
Effectiveness and Clinical Usefulness of Electronic Agenda Setting in Psychiatric Practices: A South Texas Psychiatric PBRN Study Cervando Martinez Jr.,
Hanneke van der Lee, MD, PhD
Adnan Hajjiah Critical Care Pharmacist MSc Clinical Pharmacy, MPharm
Kandeke C, Chibuta C, Banda D
Perceived barriers and facilitators to adherence to antiretroviral therapy among persons living with HIV in the Upper East Region Dr. Gifty Apiung Aninanya,
Victoria Gemmell1 Professor Alex Mullen2
Module 5: Acceptability
Pharmacy practice and the healthcare system Ola Ali Nassr
Evaluation of the Use and Knowledge of Unlicensed Medication
Developing Medicines for Children
Use of emollients and topical glucocorticoids among adolescents with eczema: data from the population-based birth cohort BAMSE S. Lundin,1,2 C.F. Wahlgren,3,4.
Pediatric Drug Development A Regulatory Perspective
Atopic dermatitis, educational attainment and psychological functioning: a national cohort study Authors: Jevgenija Smirnova1,2, Laura von Kobyletzki1,3,
David Wright Professor of Pharmacy practice University of East Anglia
Presentation transcript:

Synnöve Lindemalm, MD, PhD, Astrid Lindgren Children's Hospital In-situ coating of tablets and capsules - tolerance and acceptance in pediatric patients Ranaa El Edelbi MSc Pharm, PhD student , Astrid Lindgren Children's Hospital , Staffan Eksborg professor, Astrid Lindgren Children's Hospital, Synnöve Lindemalm, MD, PhD, Astrid Lindgren Children's Hospital Methods A non-randomized intervention study was performed at Astrid Lindgren Children´s Hospital. A total number of 78 pediatric patients were included in the study (43 females and 35 males). The ability of patients (median age 9 years; range 2-17 years) to swallow tablets/capsules was evaluated by questionnaires. Results Swallowing ability and palatability was improved by in-situ coating. Sixty-six out of 77 pediatric patients (86%; 95%CI: 76 to 93%) reported facilitated drug treatment after in-situ coating (Figure 1.). Many children included in our study were able to swallow tablets and capsules larger than those proposed by EMA (European Medicines Agency), (Fig ure 2.). Introduction To swallow tablets/capsules is challenging in pediatric oral drug treatment. Factors that influence the childrens ability to swallow include taste, smell and texture. Children and older adults share similarities in drug acceptability and swallowing ability for tablets and capsules. Appropriate formulations are therefore crucial to increase the acceptability of medicines in order to improve therapeutic outcome, safety and compliance . MedCoat® is an in-situ coating device aimed to facilitate swallowing and hide unpleasant taste for tablets/capsules. Aim To study tolerance and acceptance in pediatric patients for MedCoat® in-situ coating of tablets/capsules. Figure 2. Tablets/capsules size intake in different age groups The longest tablets/capsules sizes that were swallowed by the 3 study groups before the use of in-situ coating. The shaded part of each study groups refers to the size interval proposed by EMA (European Medicines Agency). Conclusion: Drug therapy was facilitated and in-situ coating was well accepted and tolerated for most pediatric patients. Figure 1. Facilitation of in-situ coating in different age groups All pediatric patients reported difficulty to swallow tablets/capsules before the use of in-situ coating. The striped columns show number of patients where drug treatment improved. The open columns show not improved drug treatment after first in-situ coated dose. ACKNOWLEDGEMENTS Financial support was provided through the regional agreement on medical training and clinical research (ALF), project 20130324, between Stockholm County Council and Karolinska Institutet for all authors. MedCoat AB for supporting the study with MedCoat® samples and placebo tablets. Pediatric nurses at Astrid Lindgren Children’s Hospital and pharmacist student Nora Shabo who helped us conduct the study. References 1. Liu F, Ranmal S, Batchelor HK, Orlu-Gul M, Ernest TB, Thomas IW, et al. Patient-centred pharmaceutical design to improve acceptability of medicines: similarities and differences in paediatric and geriatric populations. Drugs 2014; 74:1871-89. 2. Kimland E, Nydert P, Odlind V, Bottiger Y, Lindemalm S. Paediatric drug use with focus on off-label prescriptions at Swedish hospitals - a nationwide study. Acta Paediatr 2012; 101:772-8. 3. Kolch M, Schnoor K, Fegert JM. The EU-regulation on medicinal products for paediatric use: impacts on child and adolescent psychiatry and clinical research with minors. Eur Child Adolesc Psychiatry 2007; 16:229-35. 4. Agency EM. Clinical Investigation of Medicinal Products in the Paediatric Population CPMP⁄ ICH ⁄ 2711 ⁄ 99. ICH Topic E 11. 5. El edelbi R, Eksborg S, Lindemalm S. In-situ coating of tablets and capsules - tolerance and acceptance in pediatric patients. Acta Paediatr 2015 (in press). Karolinska Institutet Ranaa El Edelbi PhD student, Dep. Of women´s and children´s Health. Karolinska University Hospital Ranaa El Edelbi Astrid Lindgren Children’s Hospital H2:03 • 171 76 Stockholm, Sweden E-post: Ranaa.el-edelbi@karolinska.se Phone: +46735779906